Systems analysis of miRNA biomarkers to inform drug safety
| Autor: | Louise Y. Takeshita, Alan Norris, Ania Wilczynska, Amy Schofield, Robert Sutton, Jens Allmer, Lawrence Howell, Eunice Zhang, Matthias Hackl, Shiva S. Forootan, Paul Reeves, Mika Remes, Stephen Lee, Francesco Falciani, Joseph P Brown, Warren E. Glaab, James W. Dear, Jack Brown, Christopher E. Goldring, B. Kevin Park, Catherine C. Bell |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Drug
Drug-Related Side Effects and Adverse Reactions Health Toxicology and Mutagenesis Systems biology media_common.quotation_subject Computational biology Disease Review Article Toxicology Sensitivity and Specificity Biomarkers Pharmacological 03 medical and health sciences 0302 clinical medicine Drug Safety microRNA Medicine Humans Organ system 030304 developmental biology media_common 0303 health sciences business.industry Systems Biology General Medicine Biomarker 3. Good health MicroRNAs Systems analysis 030220 oncology & carcinogenesis GTB Tuinbouw Technologie Biomarker (medicine) Assay standardization DILI business |
| Zdroj: | Archives of Toxicology, 95(11), 3475-3495 Archives of Toxicology ARCHIVES OF TOXICOLOGY Archives of Toxicology 95 (2021) 11 Schofield, A L, Brown, J P, Brown, J, Wilczynska, A, Bell, C, Glaab, W E, Hackl, M, Howell, L, Lee, S, Dear, J W, Remes, M, Reeves, P, Zhang, E, Allmer, J, Norrish, A, Falciani, F, Takeshita, L Y, Forootan, S S, Sutton, R, Park, B K & Goldring, C 2021, ' Systems Analysis of miRNA Biomarkers to Inform Drug Safety ', Archives of toxicology . https://doi.org/10.1007/s00204-021-03150-9 |
| ISSN: | 0340-5761 |
| DOI: | 10.1007/s00204-021-03150-9 |
| Popis: | microRNAs (miRNAs or miRs) are short non-coding RNA molecules which have been shown to be dysregulated and released into the extracellular milieu as a result of many drug and non-drug-induced pathologies in different organ systems. Consequently, circulating miRs have been proposed as useful biomarkers of many disease states, including drug-induced tissue injury. miRs have shown potential to support or even replace the existing traditional biomarkers of drug-induced toxicity in terms of sensitivity and specificity, and there is some evidence for their improved diagnostic and prognostic value. However, several pre-analytical and analytical challenges, mainly associated with assay standardization, require solutions before circulating miRs can be successfully translated into the clinic. This review will consider the value and potential for the use of circulating miRs in drug-safety assessment and describe a systems approach to the analysis of the miRNAome in the discovery setting, as well as highlighting standardization issues that at this stage prevent their clinical use as biomarkers. Highlighting these challenges will hopefully drive future research into finding appropriate solutions, and eventually circulating miRs may be translated to the clinic where their undoubted biomarker potential can be used to benefit patients in rapid, easy to use, point-of-care test systems. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink